HCPCS Code J2469: Injection, Palonosetron HCl, 25 µg

Use HCPCS code J2469 to report palonosetron HCl injections, 25 mcg, with guidance on therapeutic dose, documentation, and billing modifiers.

Use Code

## **What is palonosetron HCl?** HCPCS code J2469 refers to “Injection, palonosetron HCl, 25 micrograms.” Palonosetron, marketed under the brand name Aloxi, is a 5-HT3 receptor antagonist used as an antiemetic to prevent chemotherapy-induced nausea and vomiting (CINV). It is given intravenously and is FDA-approved for use in adults and children aged one month and older. Each billing unit of J2469 represents 25 micrograms of palonosetron HCl. Since a standard single-dose vial contains 0.25 mg (250 mcg), a complete therapeutic dose is billed as 10 units under J2469. Clear documentation of dose preparation procedures—including how the vial was drawn, how much was administered, and any wastage—is required for compliance. Palonosetron is preferred in many oncology settings due to its longer half-life compared with older 5-HT3 antagonists, reducing the need for repeated dosing. It is distinct from other antiemetics like ondansetron (J2405) or granisetron (J1626), which are billed with their own HCPCS codes.

## **J2469 documentation requirements** Accurate documentation is essential to demonstrate medical necessity and ensure correct reimbursement. ### **Medical necessity and indication** Document the chemotherapy regimen and the risk of nausea and vomiting. Record why palonosetron is clinically appropriate (e.g., highly emetogenic chemotherapy or prior intolerance to alternative antiemetics). The indication should align with FDA-approved labeling and payer policy. ### **Drug details and dosing** Record the exact drug name, palonosetron HCl, strength, concentration, and dose administered. Specify vial size (e.g., 0.25 mg/5 mL single-use vial) and wastage if applicable. Include the start and stop time of administration. ### **Units billed** State the total dose in micrograms and the corresponding billing units. For example, a 0.25 mg dose equals 250 mcg = 10 billing units under J2469. If wastage is claimed, document the discarded amount and use the JW modifier when required by the payer. ### **Prescription and order** A signed provider order should specify palonosetron, the route of administration (IV), dosage, and frequency. Maintain a copy of the chemotherapy protocol or antiemetic regimen in the patient’s record. ### **Proof of administration** Nursing notes should confirm IV administration, patient response, and any adverse effects. This serves as both clinical and billing support.

## **J2469 billing requirements** Bill J2469 is based on the 25 mcg unit size. Make sure to comply with the following criteria: ### **Code selection and units** Report one unit per 25 mcg. For a standard 0.25 mg (250 mcg) dose, submit 10 units on a single claim line. ### **Waste billing** If part of a single-use vial is not administered, the wasted amount may be billed with the JW modifier when payer policy allows. Clearly document the discarded volume. ### **Coverage** Medicare and most private payers cover J2469 when used as part of a chemotherapy antiemetic regimen. Coverage may depend on the chemotherapy protocol and whether the drug is listed as reasonable and necessary under the payer’s policy. ### **Frequency and limits** Payers may restrict frequency to once per chemotherapy cycle, reflecting the drug’s long half-life. Documentation should confirm the clinical appropriateness of dosing.

## **J2469 applicable modifiers** Use these modifiers to indicate wastage, zero wastage, or coverage status when billing palonosetron HCl: - **JW**: Drug amount discarded/not administered from a single-use vial. - **JZ**: Zero drug wastage; report when no portion of a single-dose vial is discarded (Medicare requirement). - **GA/GZ**: If an Advance Beneficiary Notice (ABN) is issued or expected denial occurs.

## **Other relevant codes** If palonosetron is not the antiemetic being used, or if another drug is chosen for the chemotherapy regimen, consider these related HCPCS codes for alternative 5-HT3 antagonists or other antiemetic agents. - **J2405**: Injection, ondansetron hydrochloride, per 1 mg - **J1626**: Injection, granisetron hydrochloride, 100 mcg - **J1453**: Injection, fosaprepitant, 1 mg

Frequently asked questions

That is 250 µg / 25 µg per unit, which equals 10 units of J2469.

No. Use J2468 for Posfrea™ as it is not therapeutically equivalent. Mixing the codes may lead to claim denial.

Typically, one dose per chemotherapy treatment cycle. Overuse (e.g., daily dosing) may result in denial; therefore, documentation must align with dosing guidelines.